|
Post by captainwalker on Nov 26, 2014 11:09:18 GMT -5
Ha! This made my day...
|
|
|
Post by otherottawaguy on Nov 27, 2014 11:03:56 GMT -5
Going short I might be scared to do but could at least buy some puts.
|
|
|
Post by kc on Nov 28, 2014 1:13:05 GMT -5
New article Nov 26, 2014 Subject: Sanofi's pre-game show on Afrezza has MannKind followers chattering www.fiercepharma.com/story/sanofis-pre-game-show-afrezza-has-mannkind-followers-chattering/2014-11-26?utm_medium=rss&utm_source=rss&utm_campaign=MannKind fans and critics line up for Sanofi's Afrezza pre-game show November 26, 2014 | By Tracy Staton Afrezza's inhaled insulin drug/device combination--Courtesy of Mannkind Who doesn't like to watch a drug launch? It's pharma's version of a spectator sport, complete with cheerleaders (and boo-ers). And for Sanofi's ($SNY) upcoming rollout of Afrezza, the inhaled insulin developed by MannKind, the crowd is already assembling. Two reasons: One, Afrezza's road to market was long, and MannKind ($MNKD) developed a host of enthusiastic fans and rabid critics as time went by. Two, Sanofi's diabetes business is under a spotlight, thanks to former CEO Chris Viehbacher's abrupt departure, not to mention the pessimistic forecasts he issued just before he left. So, at Sanofi's investor confab late last week, a certain share of visitors zeroed right in on any comments about Afrezza--and any hints they might give about Sanofi's launch plans and their likelihood of success. Some observers noted that Sanofi didn't trot out any physicians to talk up Afrezza, as it did with other soon-to-be-launched meds like Toujeo (the Lantus follow-up) and LixiLan (the Lantus-Lyxumia combo med). Bad sign, some said. Good sign, said others, noting that the docs discussed meds that aren't yet approved in the U.S. Splitting hairs? Maybe. The hard and fast info on Afrezza's launch was scarce. Sanofi's Riccardo Perfetti, senior medical officer in diabetes, did say the company plans to target diabetic patients who don't want to start insulin therapy--and that's a lot of diabetics, given the fact that two-thirds of patients resist the move. On average, patients wait 5 years to add insulin to their oral meds. Another target: Patients who are using a basal insulin like Lantus but need another insulin at mealtimes. Those patient populations, combined, could reach 3 million, RBC analyst Adnan Butt said in a recent investor note. Selling points? No injections, obviously. As an inhaled insulin, Afrezza is an odd duck that could just possibly grow up to be a big-selling swan. According to Sanofi's market research, 39% of patients using oral meds didn't want to start insulin therapy specifically because they wanted to avoid injections. To about 60% of surveyed patients, Afrezza was a preferable alternative to a pen injector. Almost as many said they'd prefer to use Afrezza daily than add injections at mealtime. Meanwhile, Sanofi is preparing to test other Afrezza dosing regimens, hoping to get some positive tweaks to the drug's official labeling. It's in negotiations with the FDA on post-approval studies. Launch date is still set for the first quarter of next year, regardless of change at the top of Sanofi.
|
|
|
Post by brentie on Nov 28, 2014 14:38:19 GMT -5
|
|
|
Post by brentie on Nov 28, 2014 15:07:30 GMT -5
|
|
|
Post by ezrasfund on Dec 1, 2014 9:34:45 GMT -5
|
|
|
Post by nemzter on Dec 4, 2014 12:57:14 GMT -5
247wallst.com/healthcare-business/2014/12/04/mannkind-sees-more-insider-selling/MannKind Sees More Insider Selling MannKind Corp. (NASDAQ: MNKD) saw its shares trading lower on Thursday, on what was a day with little or no real news from the company. The culprit may simply be insiders selling more shares. One thing that should be pointed out first and foremost is that these shares sold were part of a scheduled insider share sale under the formal Rule 10B5-1 Plan. The total proceeds between these two insider sales came to more than $1.4 million — versus a market cap of about $2.3 billion. A second issue to consider is that other insiders also sold over 250,000 shares later in November as well. Diane Palumbo, Vice President of Human Resources, sold some 183,522 shares on December 1 at a volume weight average price (VWAP) of $5.8943, for just over $1 million in total proceeds. She still has 29,105 shares. Hakam Edstrom, president, sold some 74,668 shares on December 1 at a VWAP of $5.8937 per share, for a total of about $440,000. Edstrom is shown to have 1.047 million shares remaining. The logic over insider selling is far more complicated than open market share purchases by corporate insiders. The insiders may be doing estate planning, they may be buying a house or there may be myriad other reasons. Again, these two insider sales were under a Rule 10B5-1 Plan, so they are likely less than ominous on the surface. Still, with MannKind shares having been cut in half, and with so many skeptics fighting optimists here, it is easier to see why some investors might wonder about large blocks of stock being sold. There is still a debate over Sanofi’s involvement, or the terms of that deal, for Afrezza as an inhaled insulin. Our view after the sell-off began taking root was that the deal just might not be good enough for MannKind. That remains a debate to this day, as Thomson Reuters has consensus estimates calling for a loss in 2015 on only $41.55 million in revenues. Still, the most optimistic forecast is $110 million. Many investors and traders think this is the next great blockbuster — and many are betting against it. To prove a point, the November 14 short interest of 82,431,190 shares was a record for 2014 and represented more than 17 days to cover. MannKind shares were down 4% at $5.47 in mid-day trading on Thursday. MannKind’s 52-week trading range is $3.80 to $11.48, and the consensus analyst price target remains just under $9.
|
|
|
Post by brentie on Dec 5, 2014 10:16:58 GMT -5
|
|
|
Post by afrizzle on Dec 5, 2014 15:42:29 GMT -5
This article had a mail it in sort of feel. Not even a good attempt at a shorty bash.
|
|
|
Post by dreamboatcruise on Dec 5, 2014 16:29:06 GMT -5
I think I should have been paid the penny for reading it rather than the author getting one. I find your latest cavatar more interesting than that article. One always hears about dead cats bouncing. Who knew lives ones don't. Though I do appreciate this brave kitty taking one, on what appears to be the chin, for scientific exploration.
|
|
|
Post by jpg on Dec 6, 2014 0:43:41 GMT -5
Not directly related to Mannkind but still interesting. How much would Mannkind be worth? Don't know but I would venture to say a lot more then now... JPG Merck in talks to acquire Cubist for over $8 billion www.cnbc.com/id/102245250
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 6, 2014 10:14:39 GMT -5
|
|
|
Post by brentie on Dec 6, 2014 14:30:36 GMT -5
|
|
|
Post by Chris-C on Dec 6, 2014 15:57:20 GMT -5
I think I should have been paid the penny for reading it rather than the author getting one. I find your latest cavatar more interesting than that article. One always hears about dead cats bouncing. Who knew lives ones don't. Though I do appreciate this brave kitty taking one, on what appears to be the chin, for scientific exploration. I love your humor, Dream; as I am kept by a cat who keeps me incredibly humble every day. She never lets us forget that cats were worshiped as gods during ancient Egyptian times. Thus, any cat humbling itself as a volunteer for a scientific experiment is indeed worth a laugh. Anyway, you have my vote for the Pro Boards court-jester-in-chief designation. Good luck to you Sir, and thanks for helping us stay lighthearted during the dark days of dead money (and fictitious dead cat bounces)! Chris-C
|
|
|
Post by kc on Dec 7, 2014 22:09:41 GMT -5
|
|